J&J, Takeda recall contaminated Velcade

Particle contamination in vials of the blood-cancer drug Velcade are driving a recall that touches North America, Europe and Asia. The precautionary action follows five reports of post-reconstitution visible particles, reports Bloomberg.

A fix to the "manufacturing problem" is already in the works, according to Takeda, whose Millennium Pharmaceuticals group co-markets the drug with Johnson & Johnson's ($JNJ) Janssen-Cilag unit. The contaminant is a "white polyester-like material that stemmed from a filtration system," reports PBR Regulatory Affairs.

The particles were found in vials from two batches made for Millennium by a contract manufacturer. Janssen-Cilag is recalling all remaining stock of six batches distributed between January and June this year.

Velcade is co-developed by Millennium and J&J's Ortho Biotech Oncology Research & Development unit. Millennium has commercialization rights in the U.S.; Janssen-Cilag, in Europe and the rest of the world. No adverse events have been reported.

- see the article
- here's the Bloomberg report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.